Skip to main content
SpringerLink
Log in

A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

The effects of a low dose of rosuvastatin (ROS) and pitavastatin (PIT) on lipid profiles and inflammation markers were assessed in subjects with type 2 diabetes mellitus.

Methods

A total of 90 Japanese type 2 diabetes patients with hyperlipidemia (low-density lipoprotein cholesterol [LDL-C] ≥140 mg/dL) were enrolled in this study. They were randomly assigned to four groups with open-label treatment with ROS (2.5 mg daily) or PIT (2 mg daily); two groups were sequentially treated with both drugs, with crossover of medication after 12 weeks, and the other two groups underwent treatment with either ROS or PIT for 24 weeks. The primary endpoints were the percentage changes in LDL-C, high-density lipoprotein cholesterol (HDL-C) and triglyceride, and the LDL-C/HDL-C ratio.

Results

Both ROS and PIT lowered LDL-C and triglyceride, and increased HDL-C. In particular, significantly greater reduction in LDL-C was seen with ROS (−44.1%) than with PIT (−36.9%, P<0.01) in the crossover group from ROS to PIT, and the same result was detected in the crossover group from PIT (−34.8%) to ROS (−44.7%). The ratio of LDL-C/HDL-C was significantly reduced with ROS treatment (from 3.45 to 1.85) compared with that with PIT (from 3.45 to 2.22, P<0.01). Both ROS and PIT lowered plasma levels of highsensitivity C-reactive protein (hsCRP), tumor necrosis factor (TNF)-alpha, and plasminogen activator inhibitor-1 (PAI-1). In addition, the hsCRP level with the administration of ROS was significantly improved compared with the administration of PIT. There was no significant correlation between changes in LDL-C and hsCRP, TNF-alpha, and PAI-1 levels. ROS and PIT did not have an adverse effect on glycemic control in type 2 diabetes patients.

Conclusion

Therapy with both statins improved lipid profiles and reduced proinflammatory responses; however, 2.5 mg of ROS have a potent LDL-C-lowering and hsCRP-lowering effect compared with 2 mg of PIT in patients with diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Greving JP, Denig P, Ceeuw D, Bilo HJK, Haaijer-Ruskamp FM. Trend in hyperlipidemia and hypertension management in type 2 diabetes from 1998–2004: a longitudinal observational study. Cardiovasc Diabetol. 2007;6:25.

    Article  PubMed  Google Scholar 

  2. Colhoun HM, Betteridge DJ, Dumington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomized placebo-controlled trial. Lancet. 2004;364:685–696.

    Article  PubMed  CAS  Google Scholar 

  3. Betteridge J. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118(Suppl. 12A):10–15.

    Article  PubMed  Google Scholar 

  4. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, highdensity lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499–508.

    Article  PubMed  CAS  Google Scholar 

  5. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175–1182.

    Article  PubMed  CAS  Google Scholar 

  6. Saito Y, Yamada N, Teramoto T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002;162:373–379.

    Article  PubMed  CAS  Google Scholar 

  7. Effects of pitavastatin, 3-hyfroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb. 2009;16:539–545.

    Google Scholar 

  8. Arai H, Hiro T, Kimura T, et al. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome—sub-analysis of Japan-ACS study. J Atheroscler Thromb. 2010;17:1096–1107.

    Article  PubMed  CAS  Google Scholar 

  9. Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipidlowering arm (ASCOT-LLA). Diabetes Care. 2005;28:1151–1157.

    Article  PubMed  CAS  Google Scholar 

  10. Peters SAE, Palmer MK, Grobbee DE, et al. C-reactive protein lowering with rosuvastatin in the METEOR study. J Intern Med. 2010;268:155–161.

    Article  PubMed  CAS  Google Scholar 

  11. Wlodarczyk J, Sullivan D, Smith M. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-tohead randomized controlled trials. Am J Cardiol. 2008;102:1654–1662.

    Article  PubMed  CAS  Google Scholar 

  12. Yokote K, Bujo H, Hanaoka H, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients. Collaborative study on hypercholesterolemia during intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis. 2008; 201:345–352.

    Article  PubMed  CAS  Google Scholar 

  13. Toi T, Taguchi I, Yoneda S, et al. Early effect of lipidlowering therapy with pitavastatin on regression of coronary atherosclerotic plaque-comparison with atorvastatin-. Circ J. 2009;73:1466–1472.

    Article  PubMed  CAS  Google Scholar 

  14. Teramoto T, Sasaki J, Uematsu H, et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular disease for Japanese. J Atheroscler Thromb. 2007; 14:45–50.

    Article  PubMed  CAS  Google Scholar 

  15. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347:1557–1565.

    Article  PubMed  CAS  Google Scholar 

  16. Wang TJ, Nam BH, Wilson PW, et al. Association of C-reactive protein with carotid atherosclerosis in men and women: The Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2002;22:1662–1667.

    Article  PubMed  CAS  Google Scholar 

  17. Hashimoto K, Kasayama S, Yamamoto H, Kurebayashi S, Kawase I, Koga M. Strong association of C-reactive protein with body mass index and 2-h post-challenge glucose in non-diabetic, nonsmoker subjects without hypertension. Diabet Med. 2004;21:581–585.

    Article  PubMed  CAS  Google Scholar 

  18. Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med. 1999;340:115–126.

    Article  PubMed  CAS  Google Scholar 

  19. Taniguchi A, Nagasaka S, Fukushima M, et al. C-reactive protein and insulin resistance in non-obese Japanese type 2 diabetic patients. Metabolism. 2002;51:1578–1581.

    Article  PubMed  CAS  Google Scholar 

  20. Tsunoda K, Arita M, Yukawa M, et al. Retinopathy and hypertension affect serum high-sensitivity C-reactive protein levels in type 2 diabetic patients. J Diabetes Complications. 2005;19:123–127.

    Article  PubMed  Google Scholar 

  21. Koshiyama H, Taniguchi A, Tanaka K, et al. Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai investigation of statin for hyperlipidemic intervention in metabolism and endocrinology (KISHIMEN) investigators. J Atheroscler Thromb. 2008;15:345–350.

    Article  PubMed  CAS  Google Scholar 

  22. Motomura T, Okamoto M, Kitamura T, et al. Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetes patients. J Atheroscler Thromb. 2009;16:546–552.

    Article  PubMed  CAS  Google Scholar 

  23. Qu HY, Xiao YW, Jiang GH, et al. Effect of atorvastatin versus rosuvastatin on levels of serum lipids inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res. 2009;26:958–964.

    Article  PubMed  CAS  Google Scholar 

  24. Gomez-Garcia A, Martines Torres G, Ortega-Pierres LE, Rodriguez-Ayala E, Alvarez-Aguilar C. Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia. Rev Esp Cardiol. 2007;60:1242–1249.

    Article  PubMed  Google Scholar 

  25. Bellia A, Rizza S, Galli A, et al. Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes. Atherosclerosis. 2010;210:199–201.

    Article  PubMed  CAS  Google Scholar 

  26. Laumen H, Skurk T, Hauner H. The HMGCoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Atherosclerosis. 2008;196:565–573.

    Article  PubMed  CAS  Google Scholar 

  27. Ohbayashi H. Pitavastatin improves serum resistin levels in patients with hypercholesterolemia. J Atheroscler Thromb. 2008;15:87–93.

    Article  PubMed  CAS  Google Scholar 

  28. Takebayashi K, Suetsugu M, Matsumoto S, Aso Y, Inukai T. Effects of rosuvastatin and colestimide on metablic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia. South Med J. 2009;102:361–368.

    Article  PubMed  Google Scholar 

  29. Tsutamoto T, Yamaji M, Kawahara C, et al. Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with nonischaemic chronic heart failure. Eur J Heart Failure. 2009;11:1195–1201.

    CAS  Google Scholar 

  30. Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2008;15:269–275.

    Article  PubMed  CAS  Google Scholar 

  31. Inami N, Nomura S, Shouzu A, et al Effects of pitavastatin on adiponectin in patients with hyperlipidemia. Pathophysiol Haemost Thromb. 2007;36:1–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology and Metabolism, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Tochigi, 321-0293, Japan

    Kazunori Yanagi, Tsuyoshi Monden, Shiori Ikeda, Mihoko Matsumura & Kikuo Kasai

Authors
  1. Kazunori Yanagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tsuyoshi Monden
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shiori Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mihoko Matsumura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kikuo Kasai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsuyoshi Monden.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yanagi, K., Monden, T., Ikeda, S. et al. A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes. Adv Therapy 28, 160–171 (2011). https://doi.org/10.1007/s12325-010-0098-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-010-0098-2

Keywords

Search

Navigation